Array BioPharma June 2018

Transcription

1 Array BioPharma June 2018

2 SAFE HARBOR STATEMENT Forward-looking statements made in the course of this presentation are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of The audience is cautioned that such forward looking statements involve risks and uncertainties, including those described in our annual report filed on form 10-K for the year ended June 30, 2017, and other filings of the Company with the Securities and Exchange Commission, which may cause the Company's actual results and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements.

3 MAXIMIZING SUCCESS OF ENCORAFENIB & BINIMETINIB IS ARRAY S TOP PRIORITY On Track for Commercialization 3 SIGNIFICANT MILESTONES ACHIEVED WITH IMPORTANT UPCOMING VALUE DRIVERS NEAR-TERM COMMERCIAL/BRAF-MUTANT MELANOMA * NDAs/MAAs/MMAs for BRAFm melanoma under review with FDA/EMA/PMDA ** Secondary endpoint: Median Overall Survival (mos) 33.6 months Phase 3 met primary endpoint: mpfs 14.9 months Global regulatory reviews FDA PDUFA June 30, 2018; FDA not currently planning to hold an ODAC PHASE 3/BRAF-MUTANT CRC Promising activity in safety lead-in reported at ASCO GI 2018 Triple combination of binimetinib, encorafenib and cetuximab was well-tolerated ǂ 8.0 months mpfs; 48% confirmed ORR, including 3 CRs I/O COLLABORATIONS/MSS CRC AND OTHER CANCERS BMS collaboration Binimetinib + nivolumab +/- ipilimumab in patients with RASm MSS CRC initiated in Sep Merck-sponsored collaboration Binimetinib + pembrolizumab +/- FOLFOX or FOLFIRI in patients with MSS CRC initiated in Dec Pfizer-sponsored collaboration Binimetinib + avelumab +/- talazoparib in patients with cancer Randomized portion of trial actively enrolling Trial active Trial active Trial to begin 3Q2018 COST SHARING Novartis reimbursement totaled $87 million in past 12 reported months BEACON CRC co-funding: Pierre Fabre (40%), Ono Pharmaceuticals (milestone payments), Merck KGaA (Erbitux supply) *COLUMBUS trial safety data available on slide 9; ** Pharmaceuticals and Medical Devices Agency, Japan; ǂ BEACON CRC trial safety data available on slide 27; RAS mutant

4 COLUMBUS FEATURED AT LEADING MEDICAL FORUMS & PUBLICATIONS 4 ORAL PRESENTATION Abstract Title: Overall Survival in COLUMBUS: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) vs Vemurafenib (VEM) or ENCO in BRAF-Mutant Melanoma (Abstract #223875) Presenter: Reinhardt Dummer, M.D. Date: June 4 INVESTOR WEBCAST Topic: COLUMBUS Overall Survival Presenter: Keith Flaherty, M.D. Date: June 4 Title: Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, openlabel, randomised phase 3 trial Lead Author: Reinhardt Dummer, M.D. Online Publication Date: March 21, 2018 Print Publication Date: May 2018 From The Lancet Oncology: Interpretation: Encorafenib plus binimetinib and encorafenib monotherapy showed favourable efficacy compared with vemurafenib. Overall, encorafenib plus binimetinib appears to have an improved tolerability profile compared with encorafenib or vemurafenib. Encorafenib plus binimetinib could represent a new treatment option for patients with BRAF-mutant melanoma.

5 COMMERCIAL READINESS ACTIVITIES WELL UNDERWAY IN ANTICIPATION OF LAUNCH PDUFA: June 30, Commercial Leadership & Infrastructure in Place Manufacturing Sales Force Medical Affairs MSLs Meeting with National and Regional KOLs Market Access Meeting with Payors, IDNs & GPOs Marketing Coming Soon Campaign

6 ENCORAFENIB & BINIMETINIB WELL-POSITIONED FOR SUCCESS Partnerships with Ono Pharmaceutical & Pierre Fabre Create a Strong Global Footprint 6 U.S. EUROPE JAPAN Other: Canada, Israel ROW South Korea Upfront & Milestone Payments: Global Development Co-Funding: Remaining Milestones: $30 million $35 million 40% 12% $415 million $159 million* Royalties: *Exchange rate as of the most recent quarter end Max. 35% above 100M combined annual sales Max. 25% above 10B combined annual sales

7 ROBUST DEVELOPMENT PIPELINE FOLLOWING BINIMETINIB + ENCORAFENIB 6 Partnered Programs In Registration Trials, 2 Wholly-owned Clinical Programs Advancing 7 Drug (Partner) Indication Target IND Phase 1 Phase 2 Phase 3 / Registration Trial Binimetinib (Ono, PF) Cancer MEK Encorafenib (Ono, PF) Cancer BRAF Selumetinib (AstraZeneca) Thyroid Cancer and NF1 MEK Danoprevir (Roche/Ascletis) Hepatitis C NS3 Protease Larotrectinib (Loxo Oncology) Cancer PanTrk Tucatinib (Seattle Genetics) Breast Cancer HER-2 Ipatasertib (Genentech) Cancer AKT Varlitinib (ASLAN) Cancer Pan-HER ARRY-797 LMNA-dilated DCM p38 ARRY-382 Cancer CSF1R Motolimod (Celgene) Cancer TLR Prexasertib (Eli Lilly) Cancer Chk-1 GDC-0575 (Genentech) Cancer Chk-1 LOXO-292 (Loxo Oncology) Cancer Ret LOXO-195 (Loxo Oncology) Cancer Trk AK-1830 (Asahi Kasei Pharma) Inflammation Trk Wholly-owned US Wholly-owned Global Collaboration

8 COLUMBUS MET PRIMARY ENDPOINT

9 COLUMBUS PHASE 3 RESULTS 9 COMBO450 demonstrated mos of 33.6 months mos 33.6 months vs months, HR (0.61), [95% CI ], p<0.001 * Primary endpoint: COMBO450 significantly improved PFS compared with vemurafenib alone ** mpfs 14.9 months vs. 7.3 months, HR (0.54), [95% CI ], p<0.001 Safety / Tolerability of COMBO450 ** Generally well-tolerated & reported AEs were overall consistent with previous ENCO/BINI combination clinical trial results in BRAF-mutant melanoma patients Grade 3/4 AEs that occurred in more than 5% of patients receiving COMBO450 were increased GGT (9%), increased blood CK (7%) and hypertension (6%) The incidence of selected any grade of AEs based on toxicities commonly associated with commercially available MEK+BRAF-inhibitor treatments included: rash (22%) serous retinopathy (20%) pyrexia (18%) photosensitivity (5%) ENCO=encorafenib; BINI=binimetinib; CI=confidence interval; COMBO450=ENCO 450 mg QD + BINI 45 mg BID * Nominal p-value; ** Dummer et al, The Lancet Oncology 2018 ǂ COLUMBUS trial design is available on slide 14

10 LIMITED USE OF POST-TRIAL IMMUNOTHERAPY Consistent with other published pivotal trials of BRAF and MEK inhibitors in BRAF-mutant advanced melanoma 10 Treatment Received After Study Drug 1 COMBO450 n=192 ENCO300 n=194 VEM n=191 Any treatment 42% 56% 62% Anti PD-1/anti PD-L1 20% 21% 25% Anti CTLA-4 17% 16% 19% Anti CTLA-4 + anti PD-1/anti PD-L1 3% 2% 2% BRAFi + MEKi 5% 14% 20% BRAFi 6% 8% 13% Chemotherapy 7% 12% 12% Other 3% 2% 7% BRAFi=BRAF inhibitor; COMBO450=encorafenib 450 mg QD + binimetinib 45 mg BID; CTLA-4=cytotoxic T-lymphocyte-associated protein 4; ENCO300=encorafenib 300 mg QD; MEKi=MEK inhibitor; PD-1=programmed death 1; PD-L1=programmed death ligand 1; VEM=vemurafenib 960 mg BID. *Multiple uses of a therapy in a single patient were only counted once in the frequency for that category of therapy; patients who received multiple categories of therapy are counted in each respective row. 1 Dummer et al, ASCO 2018

11 Months HISTORICAL OVERALL SURVIVAL BENCHMARKS IN BRAFm MELANOMA* BRAF+MEK Targeted Therapy 11 Vemurafenib + cobimetinib Dabrafenib + trametinib 35 Vemurafenib 30 Dabrafenib cobrim COMBI-D COMBI-V *Array has not conducted head-to-head studies comparing encorafenib and binimetinib against the other BRAF/MEK combination therapies, and these data come from separate Phase 3 studies. These trials were conducted under varying conditions and results may not be directly comparable. cobrim (NCT ) = vemurafenib+cobimetinib vs. vemurafenib+placebo; Lancet Oncol 2016; 17: COMBI-D (NCT ) = dabrafenib+trametinib vs. dabrafenib+placebo; Tafinlar and Mekinist prescribing information Revised 6/2017 COMBI-V (NCT ) = dabrafenib+trametinib vs. vemurafenib; Lancet 2015; 386: Mekinist and Tafinlar are registered trademarks of Novartis Pharma AG

12 $ millions PROJECTED ANNUAL REVENUE OF TAFINLAR + MEKINIST TRENDING TO EXCEED $400M IN US & $1B GLOBALLY 12 $300 $250 $200 $150 $100 $50 $0 Quarterly Revenues Novartis Reported Financial Results: Net Sales Tafinlar /Mekinist 1Q15 2Q15 3Q15 4Q15 1Q16 2Q16 3Q16 4Q16 1Q17 2Q17 3Q17 4Q17 1Q18 US Global Quarterly Revenues Highlights Approx. 50% of advanced melanoma patients have activating BRAF mutations >29,000 individuals succumb to melanoma each year across the U.S., Europe & Japan Projected Tafinlar+Mekinist rolling annual revenue trending to exceed $400M in US and >$1B globally 21% YOY growth in the US & 34% globally (Tafinlar+Mekinist BRAFm NSCLC approved in April in EU & June in US) Tafinlar (dabrafenib) & Mekinist (trametinib) are registered trademarks of Novartis Pharma AG

13 Annual Melanoma Mortality* GLOBAL MELANOMA MARKET Population Estimates 13 Melanoma Mutational Subgroups Estimated Annual Incidence Advanced/Metastatic Melanoma Patients BRAF WT ~50% BRAFm ~50% COLUMBUS population 18,000 16,000 14,000 12,000 10,000 8,000 6,000 4,000 2,000 0 US EU Japan * Based on 2018 SEER and 2012 GLOBOCAN epidemiology reports

14 COLUMBUS TRIAL DESIGN 14 PART 1, n=577 (1:1:1 Randomization) PART 2, n=344 (3:1 Randomization) Patients with BRAF V600E/V600K, advanced, unresectable or metastatic melanoma n = 921 Randomization Stratification Stage Performance Status Prior Immunotherapy COMBO450 Binimetinib (45 mg) + Encorafenib (450mg) n=192 Vemurafenib n=191 Encorafenib (300mg) n=194 COMBO300 Binimetinib (45 mg) + Encorafenib (300mg) n~260 Encorafenib (300mg) n~84 Primary Endpoint: Progression Free Survival (PFS) comparison of COMBO450 vs. vemurafenib Secondary Endpoints: PFS COMBO450 vs. encorafenib, PFS COMBO300 vs. encorafenib, Overall Survival COMBO450 vs. vemurafenib, Objective Response Rate, Safety Endpoints, QoL

15 Progression-Free Survival (%) Progression-Free Survival (%) COLUMBUS TRIAL MET PRIMARY ENDPOINT 15 Patients at risk COMBO450 VEM COMBO450 VEM Central Review Time (mo) Median PFS in months (95% CI) COMBO450 VEM 14.9 ( ) 7.3 ( ) HR (95% CI), 0.54 ( ) p<0.001 Local Review Median PFS in months (95% CI) COMBO450 VEM 14.8 ( ) 7.3 ( ) HR (95% CI), 0.49 ( ) p<0.001* *Nominal p value. BINI=binimetinib; CI=confidence interval; COMBO450=ENCO 450 mg QD + BINI 45 mg BID Patients at risk COMBO450 VEM COMBO450 VEM Time (mo)

16 Progression-Free Survival (%) Progression-Free Survival (%) PROGRESSION-FREE SURVIVAL COMBO450 vs ENCO Patients at risk COMBO450 ENCO COMBO450 ENCO Central Review Time (mo) Median PFS in months (95% CI) COMBO450 ENCO ( ) 9.6 ( ) HR (95% CI), 0.75 ( ) p=0.051 Local Review Median PFS in months (95% CI) COMBO450 ENCO ( ) 9.2 ( ) HR (95% CI), 0.68 ( ) p=0.006* *Nominal p value. BINI=binimetinib; CI=confidence interval; COMBO450=ENCO 450 mg QD + BINI 45 mg BID; ENCO=encorafenib Patients at risk COMBO450 ENCO COMBO450 ENCO Time (mo)

17 Progression-Free Survival (%) Progression-Free Survival (%) PROGRESSION-FREE SURVIVAL: ENCO300 VS VEM 17 Patients at risk ENCO300 VEM ENCO300 VEM Median PFS in months (95% CI) ENCO300 Central Review Time (mo) VEM 9.2 ( ) 7.3 ( ) HR (95% CI), 0.70 ( ) p=0.008* CI=confidence interval; ENCO=encorafenib; HR=hazard ratio; PFS=progression-free survival; VEM=vemurafenib. *Nominal p value Patients at risk ENCO300 VEM Median PFS in months (95% CI) ENCO300 VEM 9.6 ( ) 7.3 ( ) ENCO300 VEM HR (95% CI), 0.68 ( ) p=0.007* Local Review Time (mo)

18 Percentage DOSE EXPOSURE 18 Duration of exposure, weeks ENCO COMBO450 n=192 BINI ENCO300 n=192 VEM n=186 Mean (SD) 54.3 (30.9) 53.8 (31.3) 42.4 (31.2) 35.9 (29.5) Median (range) 51.2 ( ) 50.6 ( ) 31.4 ( ) 27.1 ( ) Relative Dose Intensity <50% 50 to <80% 80 to <100% 100% ENCO BINI ENCO300 VEM COMBO450 Median (range) dose intensity, % ( ) 99.6 ( ) 86.2 ( ) 94.5 ( ) BINI=binimetinib; COMBO450=ENCO 450 mg QD + BINI 45 mg BID; ENCO=encorafenib; VEM=vemurafenib. Includes only patients receiving 1 dose of study drug.

19 OVERALL SUMMARY OF SAFETY 19 Event COMBO450 n=192 Median Duration of Exposure: 51 weeks (%) ENCO300 n=192 Median Duration of Exposure: 31 weeks (%) VEM n=186 Median Duration of Exposure: 27 weeks (%) Adverse events 98 >99 >99 Grade 3/4 adverse events Adverse events leading to discontinuation Adverse events leading to dose interruption Adverse events requiring dose reduction On-treatment deaths COMBO450 most common events (occurring in 5 patients [3%]) Adverse events leading to discontinuation: ALT increased (3%), AST increased (3%) Adverse events requiring dose interruption: nausea (7%), vomiting (7%), ejection fraction decreased (5%), GGT increased (5%), pyrexia (4%), ALT increased (4%), diarrhea (3%), AST increased (3%), blood creatine phosphokinase increased (3%), abdominal pain (3%) On-treatment death: malignant melanoma (5%) ALT=alanine aminotransferase; AST=aspartate aminotransferase; BID=twice daily; BINI=binimetinib; COMBO450=ENCO 450 mg QD + BINI 45 mg BID; ENCO=encorafenib; GGT=gammaglutamyltransferase; QD=once daily; VEM=vemurafenib. Includes on-treatment deaths and deaths within 30 days of stopping study treatment.

20 COLUMBUS PART 2 RESULTS 20 Part 2 Primary Analysis comparison of PFS in patients treated with binimetinib 45mg twice daily plus encorafenib 300mg daily (COMBO300) to patients treated with encorafenib 300mg daily as a single agent mpfs 12.9 months vs. 9.2 months, HR (0.77), [95% CI, ], p=0.029* COMBO300 was generally well-tolerated and reported adverse events were consistent with results from COMBO450 in COLUMBUS Part 1 Grade 3/4 AEs that occurred in 5% of patients receiving COMBO300 were increased GGT (5%), increased CK (5%) and increased alanine aminotransferase (ALT) (5%). The incidence of selected any grade AEs of special interest, defined based on toxicities commonly associated with commercially available MEK+BRAF-inhibitor treatments for patients receiving COMBO300 included: pyrexia (17%), rash (15%), retinal pigment epithelial detachment (9%) and photosensitivity (2%). Full results from Part 2 were presented at ESMO 2017 *Nominal p value. 20

21 PHASE 3 BRAF-MUTANT CRC REGISTRATION TRIAL ADVANCING Promising BEACON CRC Safety Lead-In Activity

22 PHASE 3 BRAF-MUTANT COLORECTAL CANCER STUDY DESIGN Potential to Establish MEK + BRAF + EGFR Combination as New Standard of Care 22 Currently Enrolling SAFETY LEAD-IN COMPLETE Safety and tolerability will be assessed in patients receiving binimetinib, encorafenib and cetuximab for the treatment of BRAF V600E-mutant metastatic colorectal cancer n=30 RANDOMIZED PORTION Patient population BRAF V600E mutant >65% 2 nd -line patients <35% 3 rd -line patients n=615 Randomization Triplet Therapy Binimetinib + Encorafenib + Cetuximab n=205 Doublet Therapy Encorafenib + Cetuximab n=205 Control Arm FOLFIRI + Cetuximab or irinotecan + Cetuximab n=205 DISEASE PROGRESSION DISEASE PROGRESSION DISEASE PROGRESSION Continued follow-up for evaluation of OS Primary Endpoint: Overall survival (OS) of the triplet therapy compared to the control arm Secondary Endpoints: Address efficacy of the doublet therapy compared to the control arm, and the triplet therapy compared to the doublet therapy Other Secondary Endpoints: Progression-free survival (PFS), objective response rate (ORR), duration of response, safety and tolerability. Health related quality of life data will also be assessed The trial will be conducted at over 250 investigational sites in North America, South America, Europe and the Asia Pacific region Patient enrollment is expected to be completed in 2018

23 MONTHS MONTHS OBSERVED CLINICAL ACTIVITY FROM BEACON CRC SAFETY LEAD IN AND CERTAIN SEPARATE HISTORICAL BENCHMARKS IN 2 ND LINE+ BRAFm mcrc 23 BRAF-containing triplet regimens mos in 2 ND Line+ BRAFm mcrc* Dabrafenib, trametinib + panitumumab 1 2 nd Line+ n=91 Vemurafenib, cetuximab + irinotecan 2 2 nd Line+ n=49 Cetuximab + irinotecan 2 2 nd Line+ n=50 cetuximab + chemo 3 2 nd Line+ n = 24 cetuximab + chemo 4 2 nd Line+ n = 12 FOLFIRI 5 2 nd Line n = 23 FOLFIRI + panitumamab 5 2 nd Line n = 22 cetuximab + chemo 6 2 nd Line+ n = 22 cetuximab + irinotecan 7 1. Corcoran et al., Cancer Discovery April Kopetz et al., ASCO De Roock et al., Lancet Oncol, Ulivi et al., J Transl Med Peeters et al., ASCO Saridaki et al., PLoS One Loupakis et al., Br J Cancer nd Line+ n = 13 48% ORR in 2 nd Line+ BRAFm mcrc* Presented at 2018 ASCO-GI 8.0 mpfs in 2 nd Line+ BRAFm mcrc* Presented at 2018 ASCO-GI 21% 16% 4% 8% 6% Encorafenib, binimetinib + cetuximab 6 2 nd Line+ Safety Lead-In Dabrafenib, trametinib + panitumumab 1 2 nd Line+ Vemurafenib, cetuximab + irinotecan 2 2 nd Line+ Cetuximab + irinotecan 2 2 nd Line+ Cetuximab + chemo 3 2 nd Line+ Irinotecan 4 2 nd Line+ Encorafenib, binimetinib + cetuximab 6 2 nd Line+ Safety Lead-In Dabrafenib, trametinib + panitumumab 1 2 nd Line+ Vemurafenib, cetuximab + irinotecan 2 2 nd Line+ Cetuximab + irinotecan 2 2 nd Line+ Cetuximab + chemo 3 2 nd Line+ FOLFIRI 5 2 nd Line Panitumumab + FOLFIRI 5 2 nd Line 1. Corcoran et al., Cancer Discovery April Kopetz et al., ASCO De Roock et al., Lancet Oncol, Seymour et al., Lancet Oncol, 2013 (supplementary appendix) 5. Peeters et al., ASCO Van Cutsem et al, ASCO GI 2018 *Array has not conducted head-to-head studies comparing encorafenib and binimetinib against the other BRAF/MEK combination therapies, and these data come from separate Phase 3 and Phase 2 studies. These trials were conducted under varying conditions and results may not be directly comparable.

24 BEACON CRC SAFETY LEAD-IN 1 24 BEST OVERALL RESPONSE* PATIENTS (N=29)** N (%) CR + PR 14 (48) CR 3 (10) PR 11 (38) SD 13 (45) PD months estimated mpfs at the time of analysis 48% confirmed ORR (CR + PR) in patients with BRAF V600E mcrc 3 Complete Responses 62% confirmed ORR in the patients (10/16) who received only 1 prior line of therapy DCR 27 (93) No postbaseline tumor assessments 2 (7) A BRAF V600E mutation was identified in 29 patients; 1 treated patient was determined to have a non-v600 BRAF mutation (BRAF G466V ) *Locally assessed response per RECIST 1.1; **Patients with BRAF V600E mutations; Nonresponders per intent-to-treat analysis; CR=complete response; PD=progressive disease; PR=partial response; SD=stable disease; 1 Van Cutsem et al, ASCO GI 2018

25 Best % Change from Baseline BEACON CRC SAFETY LEAD-IN 1 25 Out of 28 patients with both BRAF V600E -mutant mcrc and a post-baseline assessment, 27 showed tumor regression Previous Regimen (n=15) 2 Previous Regimens (n=13) Of the 28 patients with a BRAF V600E mutation and a postbaseline tumor assessment, tumor regressions were observed in all but 1 patient Preliminary estimate of mpfs is 8.0 months (95% CI, months), with 7 of 29 patients (24%) still in follow-up and progression-free RECIST ORR Criteria mpfs was similar between patients who had 1 vs 2 previous regimens (median, 95% CI, 7.6 [ ] vs 8.1 [ ] months) * * * Patients mcrc=metastatic colorectal cancer. Excludes 1 patient with BRAF V600E mutation who did not have a postbaseline measurement *Patients with lymph node disease in short axis dimensions consistent with RECIST version 1.1 defined complete response. Non-responders per intent-to-treat analysis 1 Van Cutsem et al, ASCO GI 2018

26 Patient BEACON CRC SAFETY LEAD-IN 1 Combination of ENCO+BINI+CETUX achieved 8 month mpfs in BRAF-mutant CRC in Updated SLI Results Previous Regimen (n=16) 2 Previous Regimens (n=13) Still on Treatment First Confirmed Response The majority of responses were observed at first tumor assessment (6 weeks). Responses were ongoing in 6/14 responding patients (43%) at the time of the data cutoff. The other 15 patients all achieved stable disease as their best response, and among them, 9 patients (60%) had prolonged stable disease of 6 months (range, 7 12 months) Duration of Exposure (Months) mcrc=metastatic colorectal cancer; Van Cutsem et al, ASCO GI 2018 ENCO=encorafenib; BINI=binimetinib; CETUX=cetuximab

27 BEACON CRC SAFETY LEAD-IN 1 27 Grade 3/4 AEs reported in at least 10% of patients were: Fatigue (4) Urinary tract infection (3) Increased aspartate aminotransferase (AST; 3) Increased blood creatine kinase (CK; 3) Grade 3/4 skin-related AE reported was rash (Grade 3) in 1 patient (3%) The rate of Grade 3/4 skin toxicities was lower than generally observed for cetuximab alone (16%) or in combination with standard chemotherapy (18%) for mcrc 2 Two patients discontinued treatment due to AEs with one of these considered related to treatment mcrc=metastatic colorectal cancer. Excludes 1 patient with BRAF V600E mutation who did not have a postbaseline measurement 1 Van Cutsem et al, ASCO GI Erbitux (cetuximab injection, for intravenous infusion). Full Prescribing Information, Eli Lilly and Company, IN, 2016.

28 Annual CRC Mortality* GLOBAL COLORECTAL CANCER MARKET Population Estimates 28 CRC Mutational Subgroups Annual Colorectal Cancer Mortality 160, , , ,000 80,000 60,000 40,000 20,000 0 US EU Japan * Based on 2018 SEER and 2012 GLOBOCAN epidemiology reports

29 BEACON CRC COLLABORATION 29 Array is the owner of binimetinib and encorafenib and will act as the global sponsor of the study. Pierre Fabre has elected to co-fund 40% of the cost of the BEACON CRC trial. Pierre Fabre licensed commercial rights to binimetinib and encorafenib for Europe and other global markets from Array in December Merck KGaA, Darmstadt, Germany, is the owner of Erbitux outside the United States and Canada, and will supply Erbitux to all trial sites outside the United States and Canada as part of the collaboration. If successful, BEACON results would support regulatory submissions for all three parties.

30 STRATEGIC IMMUNO-ONCOLOGY PARTNERSHIPS & PORTFOLIO

31 MEK + PD-1 / PD-L1 DEVELOPMENT STRATEGY Collaborations advancing with Bristol-Myers Squibb, Merck & Pfizer 31 Based on growing body of preclinical & clinical evidence that MEK inhibition may enhance the activity of immunotherapies, Array structured 3 clinical trial collaborations investigating the safety and activity of binimetinib with leading checkpoint inhibitors Binimetinib Combo Studies I/O partner Nivolumab (PD-1) Pembrolizumab (PD-1) Avelumab (PD-L1) Initial Patient Population RASm MSS colorectal cancer MSS colorectal cancer Pancreatic cancer & NSCLC Line Therapy 2 nd or 3 rd line 1 st or 2 nd line n/a Trial Sponsor Array Merck Pfizer Triple Combination Option (+/-) Ipilimumab (CTLA-4) FOLFOX (Chemo) or FOLFIRI (Chemo) Talazoparib (PARP)

32 NEW TRIAL SECOMBIT/SEQUENTIAL COMBO IMMUNO AND TARGETED THERAPY STUDY 35 One of the most comprehensive studies assessing sequencing strategies for targeted and immunotherapies in BRAF-mutant melanoma Evaluate best sequencing approach with combination of targeted agents (binimetinib + encorafenib) and the combination of immunomodulatory antibodies (ipilimumab + nivolumab) in patients with BRAF-mutant melanoma Multicenter, international cooperative group trial sponsored by: Clinical Research Technology and Fondazione Melanoma Onlus; supported jointly by Bristol-Myers Squibb and Array (via Novartis) Patients with BRAF-Mutant Melanoma n=230 Randomization Binimetinib + Encorafenib Ipilimumab + Nivolumab Binimetinib + Encorafenib Progression Ipilimumab + Nivolumab Progression Binimetinib + Encorafenib 2 Cycles Ipilimumab + Nivolumab Progression Binimetinib + Encorafenib Primary Endpoint: Overall survival (OS) Key Secondary Endpoint: Progression free survival (PFS)

33 Randomization NEW TRIAL IMMU-TARGET IN BRAF MELANOMA PATIENTS PD-1 + MEK + BRAF Triple Combination 36 Investigate benefit of treating BRAF mutant melanoma patients with concurrent pembrolizumab (PD-1) + binimetinib (MEK) + encorafenib (BRAF) triple therapy Trial sponsor: Dr. Dirk Schadendorf, University Hospital, Essen, Germany Trial planned to enroll 140 patients Phase 1 Phase 2 Safety / Combinability of pembrolizumab + binimetinib + encorafenib Triple therapy (pembrolizumab + binimetinib + encorafenib) Defined 6 month course of therapy Triple therapy (pembrolizumab + binimetinib + encorafenib) Monotherapy (pembrolizumab) Primary Endpoint: Establish RP2D Primary Endpoint: Progression Free Survival (PFS) Secondary Endpoints: Safety, Overall Survival, Objective Response Rate

34 ARRY-382 (CSF-1R) + PEMBROLIZUMAB (PD-1) PHASE 1B TRIAL Initial signs of clinical activity demonstrated in patients with solid tumors 37 RECOMMENDED PHASE 2 DOSE ARRY mg daily in combination with pembrolizumab 2 mg/kg given intravenously every 3 weeks PATIENTS AND TUMOR TYPES 19 patients, with a median of 2 prior lines of therapy and 42% with 3 prior regimens, were treated in the study. Patients with pancreatic (n=6), colorectal (n=5), ovarian (n=3), gastric and melanoma (n=2, each), and triple negative breast cancer (n=1) were enrolled CLINICAL ACTIVITY The combination demonstrated early signs of activity, with 2 partial responses reported: 1st responder, who was treated with ARRY-382 at 200 mg, had Stage III pancreatic ductal adenocarcinoma. As of the data cut-off, this patient was on study treatment in cycle 14 (42 weeks) 2nd responder, who was treated with ARRY-382 at 300 mg, had stage IV ovarian cancer with liver metastasis. As of the data cut-off, this patient was on study treatment in cycle 8 (24 weeks) Safety/Tolerability of ARRY-382 ARRY-382 had a manageable safety profile when administered with pembrolizumab in this study Most common grade 3/4 adverse events (AEs) (>10%), regardless of causality, included increased AST, increased blood CK, rash, increased lipase, increased alkaline phosphatase (ALP), increased alanine aminotransferase (ALT) and anemia Encouraging early signs of activity in patients with tumor types that have been historically unresponsive to anti-pd1 therapies

35 ARRY-382 (CSF-1R) PHASE 1B/2 TRIAL Immuno-oncology trial in combination with pembrolizumab (PD-1) in solid tumors 38 EXPANSIONS PHASE 1B DOSE ESCALATION ARRY pembrolizumab n = 19 patients with solid tumors Establish MTD/RP2D ARRY pembrolizumab in patients with pancreatic cancer with 1 prior line of therapy and no prior treatment with immune checkpoint inhibitors ARRY pembrolizumab in patients with solid tumors who have progressed on prior PD1/PD-L1 inhibitors Primary Endpoint: MTD/RP2D (Phase 1b); ORR (expansions) Secondary Endpoint: Safety, PK/PD and standard efficacy measures ARRY pembrolizumab in patients with ovarian cancer who are platinum refractory and no prior treatment with immune checkpoint inhibitors

36 AGREEMENTS WITH PIERRE FABRE & NOVARTIS

37 STRATEGIC COLLABORATION WITH PIERRE FABRE ONCOLOGY 40 Pierre Fabre is a Strong European Commercial Partner Europe is leading geographic priority with robust emerging market capability to provide scale to collaboration Significant footprint in Oncology Development, Sales & Marketing Willing to commit significant resources to ensure binimetinib and encorafenib success Providing robust downstream economics (royalties) for ready-to-file products The agreement was reviewed and approved by the European Commission on Competition in December 2015 Benefits to Array $30 million upfront 40% funding for certain future clinical development, including Phase 3 BEACON trial Up to $425 million in potential development and commercialization milestones Robust, tiered double-digit royalties Commercialization Rights Array retains exclusive rights in: United States Canada Israel May Ono Pharmaceuticals will have exclusive rights in Japan and South Korea Pierre Fabre will have exclusive rights in all other geographies, including Europe, Asia and Latin America

38 NOVARTIS AGREEMENT FOR BINIMETINIB & ENCORAFENIB Transactions Closed on March 2, Under the Novartis agreement, Array is provided: $100 million+ net cash value Completion and/or substantial funding for all ongoing and several planned clinical trials Access to several Novartis pipeline agents for future combination trials including, but not limited to, LEE011 (CDK 4/6 inhibitor) and BYL719 (α-pi3k inhibitor) Continued clinical and commercial supply and support for technology transfer Conducting and fully funding the NRAS companion diagnostic program COST SHARING Novartis reimbursement totaled $87 million in past 12 reported months

39 SELECTED ENCORAFENIB & BINIMETINIB EXPLORATORY TRIALS 42 Indication Drug(s) Est. Patient Phase 1 Phase 1B Phase 2 Phase 3 BRAF V600+Melanoma Encorafenib + Binimetinib ± LEE011 (CDK 4/6) 179 BRAF V600+Melanoma Encorafenib + Binimetinib + Third Agent* 140 BRAF V600+Melanoma Binimetinib + Opdivo + Yervoy** 270 BRAF V600+Melanoma Encorafenib + Binimetinib + Keytruda** 140 BRAF V600+Melanoma Encorafenib + Binimetinib; Opdivo+Yervoy** 230 BRAF+Metastatic Colorectal Cancer Encorafenib + Cetuximab ± BYL719 (PI3Kα) 150 MSS Colorectal Cancer Binimetinib + Opdivo ± Yervoy <100 MSS Colorectal Cancer Binimetinib + Keytruda 220 Colorectal Cancer Binimetinib + Xalkori** <100 KRAS Non-small cell lung cancer Binimetinib + Ibrance** <100 Triple Negative Breast Cancer Binimetinib + Keytruda** <100 NF1-associated Plexiform Neurofibromas Binimetinib** <100 Solid Tumors Binimetinib + BKM120 (Pan-PI3K) <100 Pediatric Low Grade Gliomas and CNS Tumors Binimetinib** 111 LOGIC2 EBIN IMMU-TARGET SECOMBIT MErCuRIC Encorafenib + Binimetinib Encorafenib Binimetinib * Third agent: LEE011 (CDK 4/6 inhibitor), pan FGFR inhibitor, BKM120 (pan PI3K inhibitor) or c-met inhibitor; clinical pharmacology studies not listed above ** Investigator-sponsored trial (IST)

40 ARRAY FORMS SUBSIDIARY WITH ARRY-797: YARRA THERAPEUTICS p38 Inhibitor for LMNA-Related DCM

41 YARRA THERAPEUTICS ARRY p38 Inhibitor for LMNA-Related Dilated Cardiomyopathy (DCM) 44 LMNA A/C-RELATED DCM A rare, degenerative cardiovascular disease caused by mutations in the LMNA gene and characterized by poor prognosis CLINICAL DEVELOPMENT Phase 3 trial of ARRY-797 underway Phase 2 results 1 Primary Endpoint: The absolute mean change from baseline was 69 meters on the six-minute walk test (6MWT) at week 12 (baseline 6MWT ranged from 246 to 412 meters) ARRY-797 was well tolerated with most patients experiencing mild to moderate adverse events, including stomatitis, acne and upper respiratory tract infection 1 European Society of Cardiology Congress 2016

42 LMNA-RELATED DILATED CARDIOMYOPATHY (DCM) 45 LMNA-related DCM is a rare, degenerative cardiovascular disease characterized by DCM diagnosis (ejection fraction <40%, dilated ventricle) Presence of mutations in lamin A/C gene Poor prognosis, ~70% of patients have death, major cardiac event or transplant by age 45 1 By comparison, only 25% of DCM patients who do not have LMNA mutations experience similar events by age 45. Events defined as cardio vascular (CV) death, heart transplant or major cardiac event LMNA-related DCM under-diagnosed due to infrequent genetic testing Presence of LMNA mutation does not currently change treatment practice Early/mid-stage patients: ACE inhibitors, beta blockers and diuretics Advanced patients: Pacemaker/defibrillator, heart transplant U.S. Prevalence Estimate Dilated Cardiomyopathy (DCM) ~250,000 patients Idiopathic DCM ,000 patients LMNA-DCM 6-10,000 patients Diagnosed <1,000 1 M.R.G. Taylor, et al., J. Am. Coll. Cardiol. 2003;41;

43 ARRY-797 PROOF-OF-CONCEPT TRIAL LMNA-Related Dilated Cardiomyopathy (DCM) 46 LMNA-Related DCM Patients n=12 ARRY-797 (100 mg) ARRY-797 (400 mg) Crossover from lower to higher dose allowed for inadequate response Primary Endpoints: Change from baseline in 6-minute walk test (12 weeks) Secondary Endpoints Measures of left and right ventricular function Ejection fraction (Imaging study directly measures cardiac function); fractional area shortening Circulating biomarkers of cardiac function N-Terminal pro-brain Derived Natriuretic Peptide: Blood test that indirectly measures cardiac wall stress and severity and prognosis in cardiac failure Disease specific patient reported outcomes: Measures patient perception of improvement in functional status Others Patients: Prior to enrollment, all patients were identified as having stable New York Heart Association class II IIIa congestive heart failure and eleven patients had an implantable cardioverter defibrillator. All patients were receiving multiple heart failure medications. Trial Sites: Brigham and Women s Hospital/Harvard, Johns Hopkins University, Meriter Wisconsin Heart, University of Colorado, Ohio State University, Stanford University *6MWT: Integrated assessment of cardiac, respiratory, circulatory, and muscular capacity that has served as a basis for regulatory approvals of a number of drugs across therapeutic areas including cardiovascular diseases

44 ARRY-797 PROOF-OF-CONCEPT TRIAL Early & Sustained Improvements in 6 Minute Walk Test 47 6MWT Change from BL, m Wk 4 (n=12) Wk 12 (n=9) Wk 12* (n=12) Wk 24 (n=8) Wk 36 (n=8) Wk 48 (n=8) Wk 72 (n=4) Mean (SD) 47 (49) 69 (72) 71 (68) 54 (63) 63 (44) 55 (52) 59 (57) Median Change from BL, % baseline 6MWT ranged from 246 to 412 meters Mean (SD) 15 (18) 17 (23) 23 (23) 18 (23) 21 (16) 19 (19) 19 (18) Median MWT=6-minute walk test; BL=baseline. *Includes imputed data from 3 patients not completing the week 12 visit; the last-observation-carried-forward method was employed. ARRY-797 administration also resulted in sustained improvements in NT-proBNP, functional capacity and cardiac function through 48 weeks Patients who rolled over to a continuing treatment protocol maintained improvements in the 6MWT and NT-proBNP levels through 72 weeks of treatment. Other secondary endpoints measured including echocardiographic measures of left and right ventricular function and patient-reported outcomes using the Kansas City Cardiomyopathy Questionnaire (KCCQ), both mirrored the favorable improvements seen with the 6MWT. Presented at ESC, August 30, 2016 (Abstract P4981)

45 ARRY-797 PROOF-OF-CONCEPT TRIAL Tolerability Profile 48 ARRY-797 was well tolerated, with most patients experiencing mild to moderate adverse events, including stomatitis, acne and upper respiratory tract infection. None of the grade 3 / 4 adverse events were considered to be related to ARRY-797 by the investigators. Four patients discontinued the study. One patient discontinued due to availability of a heart for transplant, two patients for interventional cardiovascular procedures and one patient due to grade 2 stomatitis. Presented at ESC, August 30, 2016 (Abstract P4981)

46 HISTORICAL BENCHMARKS FOR 6 MINUTE WALK TEST 49 Product Company Indication FDA Approved 6MWT: Mean Change vs. Baseline (Absolute Meters) Bosentan Actelion PAH Yes Idursulfase Shire MPS II Yes Riociguat Elosulfase Alfa Bayer CTEPH & PAH Yes BioMarin MPS IVA Yes Ambrisentan Gilead PAH Yes Laronidase Genzyme MPS I Yes Meters

47 SELUMETINIB IN CANCER & NF1 Phase 3 / Registration Trials

48 SELUMETINIB (ASTRAZENECA) Two Registration Studies Underway 51 Key Deal Terms Potential Royalty: Double-digits Potential Milestones Remaining: $30 million specific for selumetinib Structure: AstraZeneca responsible for global development and commercialization Registration Trials ASTRA/Thyroid Cancer with RAI; complete remission rate; n=304, 1:1 randomized vs. placebo; projected top-line results 1H2018 Neurofibromatosis Type 1 (100,000 individuals in U.S.) Single agent; confirmed response rate by volumetric MRI; n=50 ENROLLMENT COMPLETE ENROLLING

49 ASTRA PHASE 3 STUDY Selumetinib in Patients with Differentiated Thyroid Cancer 52 Completed Enrollment Patients with differentiated thyroid cancer who have had a previous thyroidectomy Must be able to receive radioactive iodine therapy and thyroid stimulating hormone suppression n=304 Randomization 1:1 Five Week Treatment Selumetinib (75mg BID) + Single Dose Adjuvant Radioactive Lodine n=152 Placebo + Single Dose Adjuvant Ratioactive Lodine n=152 Primary Endpoint: Complete remission rate in overall study population Secondary Endpoints: Complete remission rate in patients with BRAF- or NRAS-mutant tumors Safety, pharmacokinetics ClinicalTrials.gov identifier: NCT

50 NO STANDARD MEDICAL THERAPIES FOR PATIENTS WITH NF1/PN 53 Neurofibromatosis type 1 (NF1) is an autosomal dominant disorder that can cause tumors to grow on nerves throughout the body 1 Most tumors are inoperable NF1 may lead to blindness, bone abnormalities, cancer, deafness, disfigurement, learning disabilities and excruciating and disabling pain NF affects one in every 3,000 individuals NF affects more than cystic fibrosis, Duchenne muscular dystrophy and Huntington s disease combined 3 Years 5 Years PN Limits Mobility of Left Arm 1 C. Widemann, M.D., N Engl J Med 2016; 375:

51 SELUMETINIB IN NF1 PEDIATRIC PATIENTS Objective Responses Seen in 71% of Patients 1 54 Partial Response (PR)* 71% (17 out of 24) Progressive Disease (PD)* 0% Common Adverse Events (AEs) Acneiform rash, asymptomatic CK elevation, GI Median Cycle (1 Cycle = 28 Days) 30 (6-56) Durability Anecdotal Observations 15 of the 17 patients with partial response maintain their response status to date (last patient recruited Feb. 2014) Decreases in tumor-related pain, disfigurement & functional impairment *PR and PD Defined by NCI investigators as a PN volumetric decrease of 20% using MRI Patient 20: the visible reduction PN burden is depicted in the MRI results and photographs before treatment as compared with those at the end of cycles 5 and 10 during treatment. 1 C. Widemann, M.D., N Engl J Med 2016; 375:

52 FINANCIALS

53 THIRD QUARTER OF FISCAL 2018 Financial Results 56 Three Months Ended March 31, December 31, Increase / March 31, Increase / (Decrease) 2017 (Decrease) Revenue Reimbursement revenue $ 24,751 $ 22,395 $ 2,356 $ 26,085 $ (1,334) Collaboration and other revenue 10,113 8,508 1,605 5,530 4,583 License and milestone revenue 31,503 11,315 20,188 1,665 29,838 Total revenue 66,367 42,218 24,149 33,280 33,087 Operating expenses Cost of partnered programs 17,712 13,716 3,996 7,432 10,280 R&D for proprietary programs 53,636 42,613 11,023 46,069 7,567 General and administrative 16,773 11,607 5,166 11,714 5,059 Total operating expenses 88,121 67,936 20,185 65,215 22,906 Loss from operations (21,754) (25,718) 3,964 (31,935) 10,181 Loss on extinguishment and conversion of Notes (6,457) 6,457 Impairment loss related to cost method investment Realized gains on investments and other (716) Change in fair value of notes payable (100) (300) 200 (1,300) 1,200 Net interest expense (1,066) (1,578) 512 (2,867) 1,801 Net loss $ (22,851) $ (34,053) $ 11,202 $ (35,317) $ 12,466 Net loss per share - basic and diluted $ (0.11) $ (0.17) $ 0.06 $ (0.21) $ 0.10 March 31, December 31, March 31, Cash, cash equivalents and marketable securities $ 439,518 $ 420,317 $ 207,392

54 CONVERTIBLE DEBT 57 Amount $126 million Term Seven year, issued November 2017 Coupon 2.625% Settlement Early Redemption Cash or stock at the option of Array; shares per $1,000 of note. This is based on conversion price of $15.46 per share. Retire the debt in stock would require ~8.1 million shares. Holders: May convert early if the last reported sale price of our common stock for at least 20 trading days (whether or not consecutive) during the period of 30 consecutive trading days ending on the last trading day of the immediately preceding fiscal quarter is greater than or equal to $15.46 (130% of the applicable conversion price) Array: May convert early if the share price is at least $20.09 (130% percent above conversion price of $15.46) AND only after four years (2021). Make Whole If the notes are called early by Array, the investors receive an additional amount for the value of the lost coupon and optionality.

55 PROFORMA FULLY DILUTED SHARE COUNT As of March 31, Number of Shares (Millions) Common Shares Outstanding 211 Exercisable Employee Equity* 5 Convertible Debt due 2024** 8 Total Fully Diluted Share Count 224 * At Array s option, convertible debt due in 2024 may be paid with 8.2 million shares of common stock or in cash at a $15.46 strike

56 TOP INVESTORS (AS OF MARCH 31, 2018) 59 Holder Name % Out Position Fidelity Management & Research Company 23,602, The Vanguard Group, Inc. 21,919, Redmile Group, LLC 17,224, BlackRock Institutional Trust Company, N.A. 14,340, Franklin Advisers, Inc. 8,183, State Street Global Advisors (US) 7,974, T. Rowe Price Associates, Inc. 6,047, Baker Bros. Advisors LP 5,656, BVF Partners L.P. 5,062, OrbiMed Advisors, LLC 4,900, Farallon Capital Management, L.L.C. 3,095, EcoR1 Capital, LLC 3,049, Driehaus Capital Management, LLC 2,696, Pinnacle Associates Ltd. 2,598, Nuveen LLC 2,505,

57 CONVERTIBLE DEBT HOLDERS (AS OF MARCH 31, 2018) 60 Holder Name Position % Out Linden Advisors LP 25, Wolverine Asset Management 19, Redmile Group LLC 19, Citadel Advisors LLC 13, Graham Capital Management LP 10, Tenor Capital Management Co LP 10, Allianz SE 9, CSS LLC 6,

58 ARRAY ANALYSTS 61 Analysts Anupam Rama Chris Shibutani Mara Goldstein Eun Yang Ted Tenthoff Stephen Willey Peter Lawson Jim Birchenough Firm JP Morgan Cowen & Co. Cantor Fitzgerald Jefferies & Co. Piper Jaffray Stifel Nicolaus SunTrust Robinson Humphrey Wells Fargo

59 THANK YOU